Brinzolamide
Based on 7 publication(s) in Google Scholar
Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research.
For research use only. We do not sell to patients.
- Purity: 99.91%
- CAS No.: 138890-62-7
- Formula: C12H21N3O5S3
- Molecular Weight:383.51
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Anti-COVID-19 Compound Library
HY-L052
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Targeted Diversity Library
HY-L099
-
EMA-Approved Drug Library
HY-L116
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Brinzolamide
More- Mater Today Bio. 2025 Aug 11:34:102179. [Abstract]
- ACS Environ Au. 2025 Aug 5;5(6):573-582. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- Anal Chem. 2020 Dec 15;92(24):15745-15756. [Abstract]
- J Pharm Biomed Anal. 2021 Feb 20:195:113870. [Abstract]
- J Pharm Innov. 2025 Oct 14;20(5):1-22.
- ETH Zurich. 2020 Dec.
Biological Activity
|
CA Ⅱ |
The pharmacokinetic parameters of Brinzolamide in rabbits[1].
| Intracameral Administration (4.5 mg) | Intracameral Administration (4.5 mg) | Topical Administration (500 mg) | Topical Administration (500 mg) | |
| PK Parameters | Aqueous Humor | Iris-Ciliary Body | Aqueous Humor | Iris-Ciliary Body |
| Tmax (h) | 0.08 | 0.5 | 1 | 0.25 |
| Cmax (ng/mL, ng/g) | 11,050 | 1964 | 408 | 1245 |
| Terminal t1/2 (h) | 3.4 | 13 | 2 | 13.6 |
| AUC0-24h (h*ng/mL, h*ng/g) | 17,780 | 7725 | 1896 | 11414 |
| AUC0-∞ (h*ng/mL, h*ng/g) | 17,836 | 8839 | 1955 | 16628 |
| Dose-normalized AUC0-∞ (h*/mL, h*/g) | 4 | 2 | 0.004 | 0.03 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rabbits[2]
-
Dosage:7.5 mg, 12 mg
-
Administration:Brinzolamide silicone matrix implant placed in the episcleral space
-
Result:Resulted in a significant IOP reduction of 4.6 mmHg on days 10-28, with concentrations of 12 mg.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 138890-62-7
-
Appearance Solid
-
Molecular Weight 383.51
-
Formula C12H21N3O5S3
-
Color Light yellow to yellow
-
SMILES
O=S(C(S1)=CC2=C1S(N(CCCOC)C[C@@H]2NCC)(=O)=O)(N)=O
-
Synonyms
AL-4862
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Mater Today Bio
Brinzolamide encapsulated β-cyclodextrin-chondroitin sulfate nanocomplexes anchored chitosan/polycaprolactone nanofibers as an ocular insert for glaucoma treatment. [Abstract]2025 Aug 11:34:102179. PMID: 40838214 -
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Anal Chem
Comparability of Raman Spectroscopic Configurations: A Large Scale Cross-Laboratory Study. [Abstract]2020 Dec 15;92(24):15745-15756. PMID: 33225709 -
J Pharm Biomed Anal
Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry. [Abstract]2021 Feb 20:195:113870. PMID: 33453569 -
-
Solvent & Solubility
DMSO : 100 mg/mL (260.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.75 mg/mL (7.17 mM); Clear solution
This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.75 mg/mL (7.17 mM); Clear solution
This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6075 mL | 13.0375 mL | 26.0749 mL | 65.1873 mL |
| 5 mM | 0.5215 mL | 2.6075 mL | 5.2150 mL | 13.0375 mL | |
| 10 mM | 0.2607 mL | 1.3037 mL | 2.6075 mL | 6.5187 mL | |
| 15 mM | 0.1738 mL | 0.8692 mL | 1.7383 mL | 4.3458 mL | |
| 20 mM | 0.1304 mL | 0.6519 mL | 1.3037 mL | 3.2594 mL | |
| 25 mM | 0.1043 mL | 0.5215 mL | 1.0430 mL | 2.6075 mL | |
| 30 mM | 0.0869 mL | 0.4346 mL | 0.8692 mL | 2.1729 mL | |
| 40 mM | 0.0652 mL | 0.3259 mL | 0.6519 mL | 1.6297 mL | |
| 50 mM | 0.0521 mL | 0.2607 mL | 0.5215 mL | 1.3037 mL | |
| 60 mM | 0.0435 mL | 0.2173 mL | 0.4346 mL | 1.0865 mL | |
| 80 mM | 0.0326 mL | 0.1630 mL | 0.3259 mL | 0.8148 mL | |
| 100 mM | 0.0261 mL | 0.1304 mL | 0.2607 mL | 0.6519 mL |
Brinzolamide Related Classifications
HY-B0588 Related Classifications
Powered by Bioz